Patents by Inventor Aurelie KAMOUN

Aurelie KAMOUN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Molecular signature and use thereof for the identification of indolent prostate cancer
    Patent number: 12123058
    Abstract: A method for predicting the risk of prostate cancer recurrence in a subject affected with prostate cancer, including: (a) providing a sample from the subject, (b) determining the TMPRSS/ERG fusion status of the sample, (c) if the sample is positive for TMPRSS/ERG fusion (Fus+), determining a molecular signature of the sample by measuring the expression level of at least 6 prostate cancer markers selected from the ANPEP, AZGP1, CHRNA2, COMP, KHDRBS3 and SFRP4, (d) comparing the molecular signature to a reference signature, and (e) assigning the subject to a risk group based on the correlation of the molecular signature with the reference signature, thereby predicting the risk of cancer recurrence in the subject.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: October 22, 2024
    Assignees: SORBONNE UNIVERSITE, CTRE RECHERCHE PATHOLOGIES PROSTATIQUES, LIGUE NATIONALE CONTRE LE CANCER, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE TOURS, CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE TOURS
    Inventors: Olivier Cussenot, Aurélie Kamoun, Aurélien De Reynies, Géraldine Cancel-Tassin, Gaëlle Fromont-Hankard
  • SYSTEMS AND METHODS FOR DETERMINING BREAST CANCER PROGNOSIS AND ASSOCIATED FEATURES
    Publication number: 20240112812
    Abstract: A computer implemented method and a machine learning model for predicting the likelihood that a subject having breast cancer will experience a relapse following treatment, predicting a tumor within a whole slide image, and/or predicting a status of a biomarker in breast cancer tissue is provided.
    Type: Application
    Filed: September 15, 2022
    Publication date: April 4, 2024
    Inventors: Charlie SAILLARD, Benoit SCHMAUCH, Victor AUBERT, Aurelie KAMOUN, Magali LACROIX-TRIKI, Ingrid GARBERIS, Damien DRUBAY, Fabrice ANDRÉ
  • SYSTEMS AND METHODS FOR DETERMINING BREAST CANCER PROGNOSIS AND ASSOCIATED FEATURES
    Publication number: 20230282362
    Abstract: A computer implemented method and a machine learning model for predicting the likelihood that a subject having breast cancer will experience a relapse following treatment, predicting a tumor within a whole slide image, and/or predicting a status of a biomarker in breast cancer tissue is provided.
    Type: Application
    Filed: March 28, 2023
    Publication date: September 7, 2023
    Inventors: Charlie SAILLARD, Benoit Schmauch, Victor Aubert, Aurelie Kamoun, Magali Lacroix-Triki, Ingrid Garberis, Damien Drubay, Fabrice André
  • Bladder cancer biomarker proteins
    Patent number: 11536724
    Abstract: The invention relates to a collection of signature peptides representing at least 10 proteins for use in cancer diagnosis and/or prognosis, to an artificial protein comprising signature peptides representing at least 10 proteins and to a nucleic acid construct encoding for such an artificial protein. The invention further relates to a collection of at least 10 proteins for use in cancer diagnosis and/or prognosis. Additionally, the invention relates to a method for cancer diagnosis and/or prognosis comprising the step of analyzing at least 10 proteins in a urine sample of a subject. Finally, the invention relates to an immunoassay product comprising antibodies for detecting at least 10 proteins.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: December 27, 2022
    Assignees: POLYQUANT GMBH, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS, LUXEMBOURG INSTITUTE OF HEALTH, INSTITUT CURIE, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III, CNIO
    Inventors: Jerome Garin, Christophe Masselon, Antonia Vlahou, Manousos Makrydakis, Ieronimos Zoidakis, Bruno Domon, Elodie Duriez, Aurelie Kamoun, Francois Radvanyi, Yves Allory, Nuria Malats Riera, Mirari Marquez Cid, Magali Court
  • MOLECULAR SIGNATURE AND USE THEREOF FOR THE IDENTIFICATION OF INDOLENT PROSTATE CANCER
    Publication number: 20210040563
    Abstract: A method for predicting the risk of prostate cancer recurrence in a subject affected with prostate cancer, including: (a) providing a sample from the subject, (b) determining the TMPRSS/ERG fusion status of the sample, (c) if the sample is positive for TMPRSS/ERG fusion (Fus+), determining a molecular signature of the sample by measuring the expression level of at least 6 prostate cancer markers selected from the ANPEP, AZGP1, CHRNA2, COMP, KHDRBS3 and SFRP4, (d) comparing the molecular signature to a reference signature, and (e) assigning the subject to a risk group based on the correlation of the molecular signature with the reference signature, thereby predicting the risk of cancer recurrence in the subject.
    Type: Application
    Filed: January 25, 2019
    Publication date: February 11, 2021
    Applicants: SORBONNE UNIVERSITE, CTRE RECHERCHE PATHOLOGIES PROSTATIQUES, LIGUE NATIONALE CONTRE LE CANCER, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE TOURS, CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE TOURS
    Inventors: Olivier CUSSENOT, Aurélie KAMOUN, Aurélien DE REYNIES, Géraldine CANCEL-TASSIN, Gaëlle FROMONT-HANKARD
  • BLADDER CANCER BIOMARKER PROTEINS
    Publication number: 20180372754
    Abstract: The invention relates to a collection of signature peptides representing at least 10 proteins for use in cancer diagnosis and/or prognosis, to an artificial protein comprising signature peptides representing at least 10 proteins and to a nucleic acid construct encoding for such an artificial protein. The invention further relates to a collection of at least 10 proteins for use in cancer diagnosis and/or prognosis. Additionally, the invention relates to a method for cancer diagnosis and/or prognosis comprising the step of analyzing at least 10 proteins in a urine sample of a subject. Finally, the invention relates to an immunoassay product comprising antibodies for detecting at least 10 proteins.
    Type: Application
    Filed: December 23, 2016
    Publication date: December 27, 2018
    Inventors: Jerome GARIN, Christophe MASSELON, Antonia VLAHOU, Manousos MAKRYDAKIS, Ieronimos ZOIDAKIS, Bruno DOMON, Elodie DURIEZ, Aurelie KAMOUN, Francois RADVANYI, Yves ALLORY, Nuria MALATS RIERA, Mirari MARQUEZ CID, Magali COURT